Avantium and WEP Collaborate to Develop POLY PEG® Technology
News Jan 20, 2006
Avantium Technologies and Warwick Effect Polymers (WEP) have announced that they have reached agreement for the joint development and commercialization of WEP’s POLY PEG® technology for (bio) pharmaceutical compounds.
POLY PEG® is a drug-delivery solution to enhance the development of therapeutic products such as peptides, monoclonal antibodies and recombinant proteins.
POLY PEG® technology has been developed to increase the bioavailability of drug molecules.
By improving the bioavailability of drug molecules and optimizing their pharmacokinetic profile, patients can benefit by decreased dosing frequencies and increased drug efficacy.
"We are very pleased to enter this agreement with Avantium," said WEP’s CTO, Professor David Haddleton.
"Avantium is a leading company in high-throughput experimentation. Their experience in PEGylation process improvement and network of contacts throughout the industry will allow us to speed the development process, while enhancing the licensing opportunities for our POLY PEG® technology."
"We welcome this opportunity to collaborate with Warwick Effect Polymers," said Tom van Aken, CEO of Avantium.
"We see great potential in WEP’s POLY PEG® technology, because it can improve and prolong the performance of drug molecules."
"We believe that our partners and future customers can benefit significantly from the collaboration between WEP and Avantium to commercialize POLY PEG® technology."
Regenerative Medicine Meets Clever Engineering to Accommodate Bone GraftsNews
Personalized bone grafts developed to repair bone defects from disease or injuryREAD MORE
Broadly Acting Antibodies Found in Blood of Ebola SurvivorsNews
Scientists have discovered a set of powerful, broadly neutralizing antibodies in the blood of Ebola survivors. In animal studies, two of these antibodies provided substantial protection against disease caused by the three species known to cause fatal human illness.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019